TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06301126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy exercise program
Description: Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy exercise program
Description: Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
Study: NCT05076812

Intervention type: DIAGNOSTIC_TEST
Intervention: measure plasma level of interleukin 38 by ELISA kit
Description: draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Intervention type: DIAGNOSTIC_TEST
Intervention: measure plasma level of interleukin 38 by ELISA kit
Description: draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Intervention type: DIAGNOSTIC_TEST
Intervention: measure plasma level of interleukin 38 by ELISA kit
Description: draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Intervention type: DIAGNOSTIC_TEST
Intervention: measure plasma level of interleukin 38 by ELISA kit
Description: draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Study: NCT01384435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Study: NCT04800991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhexium Onco Nutrition
Description: The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body
Study: NCT01384435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05213065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block with 0.5% bupivacaine
Description: Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sphenopalatine ganglion block with saline
Description: Repetitive SPG blockade using saline delivered with the Tx360® device.
Study: NCT05719701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-490
Description: Several dose groups of ICP-490 are planned for the dose exploration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-490
Description: Several dose groups of ICP-490 are planned for the dose exploration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
Study: NCT05356546

Intervention type: OTHER
Intervention: Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection
Description: Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
Study: NCT06387797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Adults (CMA+)
Description: Six cooking classes + enhanced elements, such as diabetes-specific nutrition and cooking information, and online educational information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. This arm will have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up. Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
Study: NCT00011037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)120(B,MN)GNP (vCP1452)
Description: 1 x 10\^ 7 TCID50 administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)120(B,MN)GNP (vCP1452)
Description: 1 x 10\^ 7 TCID50 administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MN rgp120/HIV-1
Description: 0.6 mg administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC(2)120(B,MN)GNP (vCP1452) placebo
Description: ALVAC placebo administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MN rgp120/HIV-1 placebo
Description: Alum placebo administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MN rgp120/HIV-1 placebo
Description: Alum placebo administered intramuscularly
Study: NCT06387797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cooking Matters for Adults (CMA)
Description: Participants will attend cooking and educational sessions once per week for 6 weeks. In addition, they will receive recipes and produce boxes with instructions to prepare the recipe at some point prior to their next class. They will also be invited to the online Google Classroom site where all intervention materials will be housed for their convenience. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up (kits provided at the final cooking class, for a total of 6 fecal samples per participant). Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
Study: NCT00012766

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Integrated team care
Study: NCT05821023

Intervention type: OTHER
Group type: OTHER
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: messages
Description: Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
Study: NCT06040710

Intervention type: DEVICE
Intervention: POSEIDON size estimation software with the EndoMind polyp detection system
Description: Polyp size estimation using the POSEIDON software and bounding boxes of the EndoMind polyp detection system.
Study: NCT06105840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure and Standardized Curcuminoid from Turmeric Extract
Description: capsules containing curcuminoid from Tumeric Extract three times a day for 3 weeks and acupressure massage at points provide comfort for knee pain twice a week for 3 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupressure and Placebo
Description: capsules containing starch three times a day for 3 weeks and acupressure massage at points that are not to provide comfort for knee pain twice a week for 3 weeks
Study: NCT05690048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transfer
Description: FMT via capsule (50 g of fecal matter) on day 0 and day 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: Vancomycin orally (125 mg 4xd, day -3 to 0).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab + Bevacizumab
Description: Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vancomycin Oral Capsule
Description: Placebo Vancomycin orally (125 mg 4xd, day -3 to 0).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fecal microbiota transfer
Description: Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21.
Study: NCT06266676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro-course
Description: The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slide presentation
Description: Provide online presentations.
Study: NCT05880433

Intervention type: DEVICE
Intervention: NIRS(INVOS 5100; Covidien Somanetics, Troy, MI
Description: NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.

Intervention type: DEVICE
Intervention: NIRS(INVOS 5100; Covidien Somanetics, Troy, MI
Description: NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
Study: NCT05199935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
Study: NCT05043753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC)
Description: Midwives perform a POC-US to measure the fetal abdominal circumference (AC) and evaluate the quantity of amniotic fluid.~In order to identify the appropriate sonographic plane the following markers need to be identified on POC-US~* Fluid filled fetal stomach on the left.~* Umbilical vein~* Umbilical portion of left portal vein within liver, as it meets the pars transversa (horizontal portion of left portal vein) seen as a right sided  L  or  C  shape.~* Fetal spine seen in cross section Amniotic fluid volume will be evaluated determining the deepest vertical pocket (DVP). Measurement is performed by assessing a pocket of maximal depth of amniotic fluid free of umbilical cord and fetal parts. The transducer is held perpendicularly to the patient's abdomen. The absence of a pocket measuring at least 2 cm in depth and 1 cm in width is indicative of oligohydramnios, while detection of a pocket measuring 8 cm or larger is suggestive of polyhydramnios (ACOG bulletin 175, 2016).
Study: NCT06291480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurologic Music Therapy
Description: Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
Study: NCT04966507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouthwash Product
Description: COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biotene Mouthwash
Description: Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
Study: NCT05865470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: smoked cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: smoked cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Oral delta-9-THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Oral delta-9-THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked Placebo
Description: Placebo Cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked Placebo
Description: Placebo Cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked Placebo
Description: Placebo Cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral Placebo
Study: NCT05074459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab Mammalian Cell Line
Description: Concentrate for solution for IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptinezumab Yeast Cell Line
Description: Concentrate for solution for IV infusion
Study: NCT05865470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral Placebo
Study: NCT04985877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult light 300
Description: 2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
Study: NCT05610527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proposed study design and randomization scenarios
Description: Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Proposed study design and randomization scenarios
Description: Present hypothetical study scenarios and assess willingness to be randomized based on the adapted 7-item Attitudes to Randomized Trials Questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments
Description: We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants

Intervention type: OTHER
Group type: OTHER
Intervention: Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments
Description: We will electronically administer Ulcerative Colitis (UC) and Crohn's Disease validated PRO instruments, including the daily symptom modules and weekly quality of life modules for 12 weeks to all 200 participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Description: In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin

Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
Description: In an Aim 3 sub study of 30% of participants, we will collect inflammatory markers commonly used to assess disease activity and risk of relapse in inflammatory bowel disease patients, including weekly blood samples of high sensitivity c-reactive protein (13 total) and monthly ferritin, albumin, and WBC, as well monthly stool specimens (4 total) for fecal calprotectin
Study: NCT05138029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection [Lucentis]
Description: The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inner limiting membrane stripping
Description: The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: The visual acuity and the thickness of the center of the macula were reviewed at 1 day, 7 days, 1 month, 3 months, and 6 months after the operation to compare the effect of the operation, and observe the cornea, anterior chamber, vitreous cavity, and intraocular pressure.
Study: NCT04774159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG Oral Tablet
Description: Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine-Placebo
Description: Colchicine-Placebo tablet
Study: NCT06336772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Shaype
Description: Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Volux
Description: Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
Study: NCT05877534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual tailored exercise
Description: A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
Study: NCT06391879

Intervention type: GENETIC
Intervention: Single cell sequencing, whole genome and metabolomic sequencing
Description: The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
Study: NCT05242900

Intervention type: PROCEDURE
Intervention: Complete decongestive therapy
Description: The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.

Intervention type: OTHER
Intervention: Standard imaging protocol
Description: The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.

Intervention type: OTHER
Intervention: Standard imaging protocol
Description: The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.

Intervention type: OTHER
Intervention: Standard imaging protocol
Description: The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
Study: NCT04796168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting (plaster of paris)
Description: Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
Study: NCT05809843

Intervention type: DEVICE
Intervention: hybrid artificial pancreas systems (CSII)
Description: artificial device that adjust the patient's glycemic levels with insulin doses appropriate to the patient's blood glucose